New breast cancer results illustrate promise and potential of I-SPY 2 trial

April 8, 2014, University of California, San Francisco

In an innovative clinical trial led by UC San Francisco, the experimental drug neratinib along with standard chemotherapy was found to be a beneficial treatment for some women with newly diagnosed, high-risk breast cancer.

Additionally, researchers learned that an algorithm used in the adaptive, randomized trial known as I-SPY 2 was highly effective at predicting the success of the treatment regimen in the patients who have HER2-positive/HR-negative disease.

The finding marks the second drug "graduation" within the I-SPY 2 trial model, which is designed to accelerate drug development and to reduce the costs of bringing safe and effective new drugs to market.

The phase 2 data was presented in San Diego at the annual meeting of the American Association for Cancer Research (AACR), a premier gathering of scientists presenting cutting edge research.

Launched by UCSF in tandem with a private-public partnership, I-SPY 2 combines personalized medicine with a novel investigational design. Its goals are to improve the efficiency of clinical and to streamline the process for developing and regimens where they are most urgently needed.

"What is so exciting about the graduations is that we're proving unconditionally that the standing trial mechanism can efficiently evaluate multiple drugs and identify the specific populations for which the agents are most effective," said Laura Esserman, MD, MBA, professor of surgery and director of the Carol Franc Buck Breast Care Center at the UCSF Helen Diller Family Comprehensive Cancer Center.

Esserman is the co-principal investigator of I-SPY 2, which is underway at 20 centers in the United States and Canada.

"We are testing the agents in high-risk patients at a time in their disease (primary breast cancer) when we are most likely to make a difference in survival," Esserman said. "This was the promise of I-SPY 2. It's what we've been waiting to see. As drugs move through the confirmation process, we should be able to accelerate availability of successful agents, see few failures in phase 3 cancer trials, and have better options for women."

Currently, it takes more than $1 billion, a dozen years and thousands of patient volunteers for a single drug to advance to market. Under the I-SPY 2 model, the costs, time and number of patients required to safely test a drug would be reduced by more than a third.

One of the innovations of the trial involves a reversal in the order of traditional therapy: surgery to remove tumors is not undertaken until after the drug treatment is completed. As a result, the response of the tumor to new therapies becomes critical evidence in gauging whether a drug is effective.

Another distinctive feature of the trial is that it screens multiple drugs from multiple companies, allowing the researchers to "graduate," drop and add drugs seamlessly throughout the course of the trial without requiring Food and Drug Administration approval for a new protocol. Consequently, the time it takes to move from one drug to another in the trial is significantly shortened.

To date, seven agents have been incorporated, two have graduated and a couple more are being prepared to enter the trial.

According to the findings presented at the AACR meeting, the algorithm randomly assigned 115 patients to the branch of the trial that contained neratinib. The results were compared with those of 78 patients who were concurrently randomized to a control arm containing standard chemotherapy.

The trial's "adaptive randomization" successfully identified HER2+/HR- as the drug's biomarker signature. It also identified two other signatures, all HER2 and MP+ tumors that might also benefit from the regimen.

Neratinib is in development at Puma Biotechnology, Inc. for the treatment of early and late-stage and under consideration for the I-SPY 3 Phase 3 trial.

"I-SPY 2 evaluates investigational regimens in patient subsets specifically defined on the basis of molecular characteristics, in order to determine whether or not adding these agents in the neoadjuvant setting is better than standard therapy alone," said trial investigator and first author John W. Park, MD, professor of medicine at the UCSF Helen Diller Family Comprehensive Cancer Center.

"We found that the algorithm used for this adaptive trial functioned as designed to increase potential assignment of neratinib to patient subgroups which appeared to benefit from the drug, while simultaneously decreasing assignments to patient subgroups which were not benefitting from the ," Park said.

Explore further: Trial identifies subset of breast cancer patients most likely to benefit from Neratinib

Related Stories

Trial identifies subset of breast cancer patients most likely to benefit from Neratinib

April 8, 2014
The I-SPY 2 trial identified a neo-adjuvant regimen containing the investigational drug neratinib and standard chemotherapy to be beneficial for hormone receptor (HR)-negative, HER2-positive primary (non-metastatic) breast ...

New presurgery combination therapy may improve outcomes for women with triple-negative breast cancer

December 13, 2013
The I-SPY 2 trial, an innovative, multidrug, phase II breast cancer trial, has yielded positive results with the first drug to complete testing in the trial. Adding the chemotherapy carboplatin and the molecularly targeted ...

Study shows new paradigm in breast cancer research

December 13, 2013
The first investigator results from an unprecedented nationwide effort to test promising new breast cancer drugs before the tumor is removed were presented during the 2013 San Antonio Breast Cancer Symposium.

New clinical trial design promises to accelerate cancer drug approvals

June 14, 2012
Patients with early-stage breast cancer usually have to wait years to receive new cancer drugs but new guidance from the Food and Drug Administration (FDA)  promises to reduce substantially the time and cost of getting ...

Pfizer reports promising results for cancer drug

April 7, 2014
An experimental drug has shown encouraging results in treating advanced breast cancer in an early clinical trial, pharmaceutical giant Pfizer reported Sunday.

Cancer drugs: better, cheaper

June 4, 2012
Cancer drug development is known to be too slow, costly and fraught with failure. Now the U.S. Food and Drug Administration is issuing recommendations for breast cancer trials that would substantially accelerate patient access ...

Recommended for you

T-cells engineered to outsmart tumors induce clinical responses in relapsed Hodgkin lymphoma

January 16, 2018
WASHINGTON-(Jan. 16, 2018)-Tumors have come up with ingenious strategies that enable them to evade detection and destruction by the immune system. So, a research team that includes Children's National Health System clinician-researchers ...

Researchers identify new treatment target for melanoma

January 16, 2018
Researchers in the Perelman School of Medicine at the University of Pennsylvania have identified a new therapeutic target for the treatment of melanoma. For decades, research has associated female sex and a history of previous ...

More evidence of link between severe gum disease and cancer risk

January 16, 2018
Data collected during a long-term health study provides additional evidence for a link between increased risk of cancer in individuals with advanced gum disease, according to a new collaborative study led by epidemiologists ...

Researchers develop a remote-controlled cancer immunotherapy system

January 15, 2018
A team of researchers has developed an ultrasound-based system that can non-invasively and remotely control genetic processes in live immune T cells so that they recognize and kill cancer cells.

Dietary fat, changes in fat metabolism may promote prostate cancer metastasis

January 15, 2018
Prostate tumors tend to be what scientists call "indolent" - so slow-growing and self-contained that many affected men die with prostate cancer, not of it. But for the percentage of men whose prostate tumors metastasize, ...

Pancreatic tumors may require a one-two-three punch

January 15, 2018
One of the many difficult things about pancreatic cancer is that tumors are resistant to most treatments because of their unique density and cell composition. However, in a new Wilmot Cancer Institute study, scientists discovered ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.